Concert Pharmaceuticals, Inc. Reports First Quarter 2014 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2014.

“We believe that Concert is well positioned to build our business as we continue to make excellent progress in advancing our pipeline. We expect to have up to five proprietary and partnered product candidates in clinical development by the end of 2014, including at least two product candidates in Phase 2 clinical trials,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals.

Help employers find you! Check out all the jobs and post your resume.